Reading this on a mobile device? Try our optimized mobile version here:

November 27, 2012
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • PET/MRI IDs head/neck lymph node spread better than DWI/MRI
    PET/MRI showed higher accuracy and sensitivity than diffusion-weighted MRI in identifying lymph node metastases in patients with head and neck cancer, according to a study presented at a radiology meeting. The PET/MR images were created by combining FDG-PET results with contrast-enhanced, T1-weighted, fat-saturated MR images, while DWI-MR images were created by merging DWI results with T1-weighted, fat-saturated MR images. "When we compared these results to available data on PET/CT, we found that PET/MRI pretty much equals the performance of PET/CT," said lead study author Dr. Christian Buchbender from the University of Düsseldorf in Germany. (free registration) (11/25) LinkedInFacebookTwitterEmail this Story
Nuclear Medicine Series
CriticalPoint is offering updated education and a way to earn ASRT
Cat A or ACPE CE
. 11 unique courses address fundamental skills while meeting the needs of Nuclear Pharmacists, Technicians and Nuclear Medicine Technologists. Register @ - limited # get FREE TRAINING using code: NUCEDU
  Clinical News & Research 
  • PET helps anticipate survival outcomes in follicular lymphoma
    PET results at an interim point and following chemotherapy may indicate survival outcomes for patients with previously untreated follicular lymphoma, according to a study in the Journal of Clinical Oncology. PET results were negative in 76% of interim patients and in 78% of final PET patients. The researchers also observed a 100% overall survival rate at two years in the final PET-negative group compared with 88% for final PET-positive patients. "The apparent better performance of PET at the end of treatment may indicate that metabolic response is slow in this indolent lymphoma and is better assessed after adequate treatment," British researchers wrote in an accompanying editorial. Healio/HemOnc Today (11/26) LinkedInFacebookTwitterEmail this Story
  • MPI used more frequently than CCTA in patients with suspected CAD
    Researchers found that SPECT MPI is used 52 times more often than coronary CT angiography in patients with suspected coronary artery disease due to reimbursement issues with CCTA and the preference for MPI among cardiologists with nuclear cameras in their offices, according to a study presented at a radiology meeting. Researchers have observed a widening trend in the discrepancy of use of these two tests. (free registration) (11/26) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Philips launches iPatient platform for CT, PET/CT systems
    Royal Philips Electronics will introduce 15 products and features at a radiology meeting this week. The products are part of its Imaging 2.0 initiative. Included in the lineup is iPatient, an advanced platform for CT and PET/CT scanners. IPatient includes a SyncRight feature that allows for the delivery of the right contrast dose and generation of consistent image quality to improve interaction between the injector and the CT system. Health Tech Zone (11/26) LinkedInFacebookTwitterEmail this Story
  • Agfa's Impax now has radiation tracking capability
    Agfa HealthCare has announced developments in its Impax Radiation Exposure Monitoring system. Impax REM, which is not yet complete, allows for automated collection and evaluation of patients' radiation exposure information. The software is intended for use by health care providers in accessing dose-tracking information from various imaging modalities. (free registration) (11/25) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Task force says some cancer tests may not be needed by patients
    An expert task force convened by the American Society of Clinical Oncology has identified several cancer-related tests and treatments that may be unnecessary for some patients. The panel advises that CT, PET and bone scans be avoided by patients with early-stage breast and prostate cancers since there is a low chance that these cancers have metastasized. In these cases, the imaging risk exceeds the possible benefits of the test, experts said. The Washington Post/Consumers Union of United States (11/27) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • EU seeks views on transparency, access to clinical trial data
    The European Medicines Agency held a workshop to gather views on access to clinical trial data and transparency. "We are not here to decide if we publish clinical trial data, but how," EMA Executive Director Guido Rasi said. The agency will create policies covering good analysis practice, rules of engagement, trial data formats, legal considerations and patient confidentiality, EMA Senior Medical Officer Hans-Georg Eichler said. PharmaTimes (U.K.) (11/26) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • 3 pressing issues facing the medical device sector
    The 2.3% medical device tax set to begin in January could pose an additional financial burden on the industry and force companies to shut down operations and cut jobs, two associates with law firm McGuireWoods say. Two other issues facing the sector are changes to the 510(k) medical device clearance process and higher costs tied to regulatory uncertainty, they note. (11/26) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Experts find obstacles to ACO development
    Researchers at the Robert Wood Johnson Medical School in New Jersey who are developing an accountable care organization have reported on a three-part approach to establishment and identified six major barriers that affect the process. The issues include conceptual, cultural, regulatory and financial barriers, researchers wrote in Health Affairs. News (11/26) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
  • Submit an abstract for the SNMMI 2013 Annual Meeting
    Abstracts are currently being accepted for the SNMMI 2013 Annual Meeting, June 8-12, 2013, in Vancouver, British Columbia. Submit an abstract on the following topics: neurosciences, general clinical specialties, molecular targeting probes -- radioactive and nonradioactive, instrumentation and data analysis, oncology: basic, translational and therapy, and oncology: clinical diagnosis. Submission deadline is Jan. 4, 2013. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

Every path hath a puddle."
--George Herbert,
Welsh-British poet, orator and priest

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.®  Legal Information